教授　平川 晃弘Akihiro Hirakawa

• Home
• Members
• 教員 Staff
• 平川 晃弘 Akihiro Hirakawa

教授

平川 晃弘 Akihiro Hirakawa

博士（工学）

学内研究者情報データベース

略歴

2004.4 - 2006.3

東京理科大学大学院工学研究科経営工学専攻 修士課程

2006.4 - 2011.3

（独）医薬品医療機器総合機構 新薬審査第一部・第五部 審査専門員

2008.4 - 2011.3

東京理科大学大学院工学研究科経営工学専攻 博士課程

2011.4 - 2012.3

東京理科大学工学部経営工学科 助教

2012.4 - 2017.3

名古屋大学医学部附属病院 先端医療・臨床研究支援センター 講師（統計解析室 室長）

2017.4 - 2020.3

東京大学大学院医学系研究科 生物統計情報学講座 特任准教授

2020.4 - 2024.9

東京医科歯科大学 病院 臨床試験管理センター / 大学院医歯学総合研究科 臨床統計学分野 教授

2024.10 -　　　

東京科学大学 大学院医歯学総合研究科 臨床統計学分野 教授

Selected Publications

1.  Hanazawa R, Sato H, Suzuki K, Hirakawa A. Applying a Statistical Model-based AI Method to Identify Prognostic Factors for Long-Term Cognitive Decline in Alzheimer’s Disease: Evidence from Pooled Placebo Data of Four Phase III Trials. International Journal of Medical Informatics, 2026 Feb 3:211:106337. doi: 10.1016/j.ijmedinf.2026.106337, 2026    
2. Asano J, Sato H, Watanabe S, Hirakawa A. Bayesian power prior in platform trials with non-concurrent control for binary outcomes: development and comparative evaluation. Statistics in Medicine, 2026 Jan;45(1-2):e70387. doi: 10.1002/sim.70387. 2026.   
3.  Kitabayashi R, Takeda K, Sato H, Hirakawa A. BOIN-MEM: A two-stage design for dose optimization with information borrowing across dose levels and stages in oncology phase I/II trials. Pharmaceutical Statistics, 2025 Nov-Dec;24(6):e70045. doi: 10.1002/pst.70045.2025  
4. Sato H, Hanazawa R, Suzuki K, Hashizume A, Hirakawa A. Self-Organized Prediction-Classification-Superposition of Longitudinal Cognitive Decline in Alzheimer's Disease: An Application to Novel Clinical Research Methodology. IEEE Journal of Biomedical and Health Informatics, 2025 Aug;29(8):5922-5935. doi: 10.1109/JBHI.2025.3546020, 2025
5. Kitabayashi R, Sato H, Nomura S, Hirakawa A. Bayesian Hierarchical Model with Adaptive Similarity Evaluation of Treatment Effects in Oncology Basket Trials. Statistics in Biopharmaceutical Research, https://doi.org/10.1080/19466315.2025.2455562, 2025 
6. Takeda K, Zhu J, Hirakawa A. BF-BOIN-ET: A Backfill Bayesian Optimal Interval Design Using Efficacy and Toxicity Outcomes for Dose Optimization. Pharmaceutical Statistics, 2025 Mar-Apr;24(2):e2470. doi: 10.1002/pst.2470, 2025   
7. Hirakawa A, Asakawa T, Tokushige K, Ozaki R, Yoshida M, Sumiyoshi Okuma H, Saito S, Shimizu Y, Kitabayashi R, Hanazawa R, Sato H, Uemura Y. Planning and Implementing Master Protocol Trials in Japan: Key Considerations of the Japanese Guideline. Clinical Pharmacology & Therapeutics, 2025 Mar;117(3):627-632. doi: 10.1002/cpt.3508, 2025.  
8. Sasaki M, Sato H, Uemura Y, Mikami A, Ichihara N, Fujitani S, Kondo M, Doi Y, Morino E, Tokita D, Ohmagari N, Sugiura W, Hirakawa A. How much more efficient are adaptive platform trials than multiple stand-alone trials? a comprehensive simulation study for streamlining drug development during a pandemic. Clinical Pharmacology & Therapeutics, 2024 Jun;115(6):1372-1382, doi: 10.1002/cpt.3224, 2024 
9. Sadachi R, Sato H, Fujiwara T, Hirakawa A. Enhancement of Bayesian optimal interval design by accounting for overdose and underdose errors trade-offs. Journal of Biopharmaceutical Statistics, 2023 Nov 15:1-20, doi: 10.1080/10543406.2023.2275766, 2023  
10. Hirakawa A, Sato H, Hanazawa R, Suzuki K; Japanese Alzheimer's Disease Neuroimaging Initiative. Estimating the longitudinal trajectory of cognitive function measurement using short-term data with different disease stages: Application in Alzheimer's disease. Statistics in Medicine. 41(21):4200-4214, doi: 10.1002/sim.9504. 2022.    
11. Hirakawa A, Sato H, Igeta M, Fujikawa K, Daimon T, Teramukai S. Regulatory issues and the potential use of Bayesian approaches for early drug approval systems in Japan. Pharmaceutical Statistics, 21: 691-695, 2022.   
12. Hirakawa A, Sudo K, Yonemori K, Sadachi R, Kinoshita F, Kobayashi Y, Okuma SH, Kawachi A, Tamura K, Fujiwara Y, Rubinstein L, Takebe N. A comparative study of longitudinal toxicities of cytotoxic drugs, molecularly targeted agents, immunomodulatory drugs, and cancer vaccines. Clinical Pharmacology & Therapeutics. 106:803-809, 2019.